Possible scenario
Delay Extends Again
20% Chance
The FDA misses the March target or issues only an interim update, citing data collection, adverse-event reconciliation, or interagency review. This preserves the status quo but prolongs uncertainty for patients, providers, manufacturers, and litigants.
Portfolio impact
S&P 5000.0%
Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.
Keeping an eye on this scenario?
Tilt can alert you when its probability or impact shifts, or send you a recommendation when it crosses a threshold.